Novel Anti-TNF Shines in Rheumatoid Arthritis Trial
A new way of inhibiting tumor necrosis factor (TNF) for treating rheumatoid arthritis showed strong results in a phase II/III clinical trial, researchers said.
About 75% to 80% of patients receiving an investigational agent called ozoralizumab achieved 20% reductions in symptoms by
Read Article